We are live on ! Find out more
IDNA icon

iShares Genomics Immunology and Healthcare ETF

51 hedge funds and large institutions have $49.1M invested in iShares Genomics Immunology and Healthcare ETF in 2025 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

42% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 12

11% more capital invested

Capital invested by funds: $44.1M → $49.1M (+$4.99M)

9% more funds holding

Funds holding: 4751 (+4)

0.37% less ownership

Funds ownership: 41.73%41.36% (-0.37%)

Holders
51
Holders Change
+4
Holders Change %
+8.51%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
17
Reduced
12
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
1
UBS Group
Switzerland
$13.2M +$166K +7,497 +1%
Bank of America
2
Bank of America
North Carolina
$6.8M +$399K +18,046 +7%
WBG
3
Wharton Business Group
Pennsylvania
$6.75M -$109K -4,950 -2%
Raymond James Financial
4
Raymond James Financial
Florida
$3.5M +$278K +12,552 +9%
PGA
5
Portland Global Advisors
Maine
$2.43M +$15.1K +684 +0.7%
Ameriprise
6
Ameriprise
Minnesota
$1.69M +$122K +5,540 +8%
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$1.68M -$66.7K -3,017 -4%
Morgan Stanley
8
Morgan Stanley
New York
$1.31M -$1.69M -76,328 -58%
Jane Street
9
Jane Street
New York
$1.21M +$158K +7,149 +16%
LPL Financial
10
LPL Financial
California
$1.17M +$71.3K +3,224 +7%
CCA
11
Clearwater Capital Advisors
Illinois
$1.04M -$507K -22,948 -34%
Lido Advisors
12
Lido Advisors
California
$748K -$52.8K -2,389 -7%
AWM
13
Avior Wealth Management
Nebraska
$672K +$10.5K +476 +2%
Commonwealth Equity Services
14
Commonwealth Equity Services
Massachusetts
$666K -$66.6K -3,011 -10%
FTUS
15
Flow Traders U.S.
New York
$655K -$391K -17,688 -39%
Cambridge Investment Research Advisors
16
Cambridge Investment Research Advisors
Iowa
$590K +$42.8K +1,934 +8%
PCA
17
Prosperity Capital Advisors
Ohio
$579K +$49.3K +2,228 +10%
Citadel Advisors
18
Citadel Advisors
Florida
$573K +$536K +24,249 New
USCWA
19
U.S. Capital Wealth Advisors
Texas
$553K -$139K -6,287 -21%
PP
20
Prudential plc
United Kingdom
$472K +$442K +20,000 New
Wells Fargo
21
Wells Fargo
California
$391K +$36.2K +1,638 +11%
OWM
22
Opes Wealth Management
California
$341K
Jones Financial Companies
23
Jones Financial Companies
Missouri
$310K +$108K +4,892 +56%
SWGC
24
Summit Wealth Group (Colorado)
Colorado
$292K +$38.6K +1,747 New
Cetera Investment Advisers
25
Cetera Investment Advisers
Illinois
$273K +$3.01K +136 +1%

IDNA Hedge Fund Activity: Q3 2025 in Review

51 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q3 2025, worth a combined $49.1M — up 11% from $44.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new IDNA positions and 5 closed out — a net gain of 4 holders — while 17 added to existing stakes and 12 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $536K. The largest seller was Morgan Stanley, cutting an estimated $1.69M.

  • 51 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q3 2025, up from 47 in Q2 2025.
  • Funds reported $49.1M of iShares Genomics Immunology and Healthcare ETF stock for Q3 2025, up 11% quarter-over-quarter.
  • 9 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q3 2025 and 5 closed out, a net change of +4 holders.
  • The largest iShares Genomics Immunology and Healthcare ETF buyer in Q3 2025 was Citadel Advisors, an estimated $536K added.
  • The largest iShares Genomics Immunology and Healthcare ETF seller in Q3 2025 was Morgan Stanley, an estimated $1.69M sold.

Based on aggregated 13F filings for Q3 2025.